Altered negative regulation of transforming growth factor β signaling in scleroderma: Potential involvement of SMURF2 in disease
- 2 July 2003
- journal article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 48 (7), 1779-1780
- https://doi.org/10.1002/art.11158
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblastsArthritis & Rheumatism, 2003
- Reconstitution of Smad3 restores TGF-β response of tissue inhibitor of metalloprotease-1 upregulation in human choriocarcinoma cellsBiochemical and Biophysical Research Communications, 2003
- Limb-Girdle Muscular Dystrophy Type 2H Associated with Mutation in TRIM32, a Putative E3-Ubiquitin–Ligase GeneAmerican Journal of Human Genetics, 2002
- Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel diseaseJCI Insight, 2001
- TGF-&bgr;/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammationJCI Insight, 2001
- TGF-β/Smad3 Signals Repress Chondrocyte Hypertrophic Differentiation and Are Required for Maintaining Articular CartilageThe Journal of cell biology, 2001
- Smad7 Binds to Smurf2 to Form an E3 Ubiquitin Ligase that Targets the TGFβ Receptor for DegradationMolecular Cell, 2000
- Smurf2 Is a Ubiquitin E3 Ligase Mediating Proteasome-dependent Degradation of Smad2 in Transforming Growth Factor-β SignalingJournal of Biological Chemistry, 2000
- TGFβ Signaling in Growth Control, Cancer, and Heritable DisordersCell, 2000
- TGF-β signalling through the Smad pathwayTrends in Cell Biology, 1997